4 studies found for:    "Opexa Therapeutics, Inc." [Exact]
Show Display Options
Rank Status Study
1 Completed Autologous T Cell Vaccine (TCV) for Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: Tovaxin Autologous T cell vaccine;   Biological: Placebo
2 Terminated Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Clinically Isolated Syndrome
Intervention: Biological: Tovaxin
3 Active, not recruiting Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Conditions: Autoimmune Diseases of the Nervous System;   Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Disease Progression;   Brain Atrophy
Interventions: Biological: Tcelna;   Biological: Placebo
4 Completed Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary Progressive
Intervention: Biological: Tovaxin Autologous T Cell Vaccine

Indicates status has not been verified in more than two years